[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1153
1. Porta N, San Juan J, Grasa MP, Simal E, Ara M, Querol MA: [Diagnostic agreement between primary care physicians and dermatologists in the health area of a referral hospital]. Actas Dermosifiliogr; 2008 Apr;99(3):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to investigate the characteristics of referrals from primary care centers to dermatology specialists as well as the correlation between the presenting complaint and the final dermatologic diagnosis.
  • The agreement between the presenting complaint and the final dermatologic diagnosis was studied.
  • Primary care physicians were found to over diagnose diseases caused by papillomavirus and the diagnostic sensitivity was very low for diseases such as basal cell carcinoma and seborrheic keratosis.
  • [MeSH-major] Dermatology. Primary Health Care. Skin Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358196.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Brumwell EP, Murphy SJ: Keratosis circumscripta revisited: a case report and review of the literature. Cutis; 2007 May;79(5):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis circumscripta revisited: a case report and review of the literature.
  • Keratosis circumscripta, also known as psoriasis circumscripta with palmoplantar keratosis, is a rarely reported condition that manifests as well-circumscribed lesions consisting of grouped folliculocentric papules on the elbows, knees, neck, sacrum, posterior axillary folds, and hips.
  • Our report contributes to this ongoing dialogue by presenting a case that supports recognizing keratosis circumscripta as a unique clinical entity.
  • We describe the diagnosis and treatment of a boy with keratosis circumscripta.
  • [MeSH-major] Keratosis / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Elbow / pathology. Exanthema / etiology. Humans. Knee / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569397.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


3. Babilas P, Knobler R, Hummel S, Gottschaller C, Maisch T, Koller M, Landthaler M, Szeimies RM: Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol; 2007 Jul;157(1):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial.
  • BACKGROUND: Photodynamic therapy (PDT) of actinic keratosis (AK) using methylaminolaevulinate (MAL) is an effective and safe treatment option, but the procedure is painful.
  • METHODS: Topical MAL-PDT was conducted in 25 patients with AK (n = 238) who were suitable for two-sided comparison.
  • The overall mean +/- SD infiltration and keratosis score at 3 months after treatment was 0.86 +/- 0.71 (LED system) vs. 1.05 +/- 0.74 (VPL device) (no statistically significant difference; P = 0.292).
  • CONCLUSIONS: VPL used for MAL-PDT is an efficient alternative for the treatment of AK that results in complete remission and cosmesis equivalent to LED irradiation but causes significantly less pain.
  • [MeSH-major] Keratosis / drug therapy. Pain / physiopathology. Photochemotherapy / adverse effects. Photosensitivity Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542980.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Moloney F, Vestergaard M, Radojkovic B, Damian D: Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol; 2010 May;162(5):1138-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses.
  • [MeSH-major] Keratosis, Actinic / drug therapy. Niacinamide / therapeutic use. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199551.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 25X51I8RD4 / Niacinamide
  •  go-up   go-down


5. Micali G, Lacarrubba F, Dinotta F, Massimino D, Nasca MR: Treating skin cancer with topical cream. Expert Opin Pharmacother; 2010 Jun;11(9):1515-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TAKE HOME MESSAGE: Topical pharmacotherapy represents an option for treatment of actinic keratoses and selected basal cell carcinomas.
  • Moreover, preliminary reports indicate imiquimod to be effective for skin or mucosal cancers such as Bowen's disease, erythroplasia of Queyrat and lentigo maligna.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408746.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Retinoids; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


6. Oyama N, Kaneko F: Trichilemmal carcinoma arising in seborrheic keratosis: a case report and published work review. J Dermatol; 2008 Dec;35(12):782-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichilemmal carcinoma arising in seborrheic keratosis: a case report and published work review.
  • The secondary skin malignancies arising in seborrheic keratosis (SK) are uncommon, and the causal association between the pre-existing lesion and subsequent malignant transformation remains uncertain.
  • Among these enigmatic conditions, trichilemmal differentiation and/or neoplasms in SK have rarely been reported thus far.
  • Herein, we describe a case of invasive trichilemmal carcinoma arising in a long-standing SK of the abdominal skin, and clinicopathologically review this rare complication with a computerized medical published work search (PubMed) and citations from earlier reports.
  • To our knowledge, only four cases of trichilemmal tumors arising in SK have been observed, and, interestingly, all cases, including ours, were Japanese.
  • Four of five cases (80%) developed the tumors in non-sun-exposed SK, and indeed had no apparent actinic damage in the histology.
  • The pre-existing SK itself is more likely to act as the primary pathogenic event for developing the secondary trichilemmal tumors than a coincidental phenomenon and a consequence of skin damage by cumulative sun exposure.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Hair Diseases / pathology. Keratosis, Seborrheic / complications. Skin Neoplasms / pathology


7. Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM: Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol; 2009 Apr;160(4):795-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Topical photodynamic therapy (PDT) is an effective method when treating extensive areas of sun-damaged skin with multiple actinic keratoses (AKs) (field cancerization) on areas such as the forehead and scalp, and offers excellent cosmetic outcome.
  • [MeSH-major] Facial Dermatoses / drug therapy. Keratosis, Actinic / drug therapy. Nerve Block / methods. Photochemotherapy / adverse effects. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210497.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


9. Bissonnette R: Chemopreventative thoughts for photodynamic therapy. Dermatol Clin; 2007 Jan;25(1):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre-clinical studies using various mouse models have shown that large surface photodynamic therapy can prevent the appearance of actinic keratoses, squamous cell carcinomas, and basal cell carcinomas.
  • Recent clinical studies also suggest that large surface photodynamic therapy can prevent the development of actinic keratoses and possibly skin cancer.
  • [MeSH-minor] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Animals. Carcinoma, Squamous Cell / prevention & control. Humans. Keratosis / drug therapy. Keratosis / prevention & control. Mice. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126747.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


10. Cox NH: Diclofenac for actinic keratoses: a formulation issue. Clin Exp Dermatol; 2006 Nov;31(6):819-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diclofenac for actinic keratoses: a formulation issue.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Diclofenac / administration & dosage. Keratosis / drug therapy. Medication Errors. Photosensitivity Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Medication Errors.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939582.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


11. Leyral C, Beylot-Barry M, Vergier B, Begueret H, Dromer C, Doutre MS, Beylot C: [Cyclosporine-induced follicular eruption]. Ann Dermatol Venereol; 2008 Jan;135(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of cyclosporine-induced follicular eruption was adopted on the basis of the histological and microbiological findings.
  • DISCUSSION: Three similar cases were previously reported characterized by typical follicular changes different from those observed in hypertrichosis or pilar keratosis.

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342076.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


12. Sánchez-Hernández M, Conesa-Zamora P, García-Solano J, Corbalán-Vélez R, Martínez-Barba E, Pérez-Guillermo M: Expression profiles of ProEx C and Ki67 in squamous cell carcinoma in situ of the skin and their relationship with human papillomavirus genotypes. J Cutan Pathol; 2010 Jul;37(7):730-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its utility in noncervical squamous cell carcinoma in situ (SCCIS) such as Bowen's disease (BD) and actinic keratosis (AK) where human papillomavirus (HPV) plays a role has not been elucidated.
  • METHODS: HPV presence was tested in SCCIS (38 BD and 7 AK) using GP5+/6+ and Short PCR fragment (SPF) primers and subsequently genotyped.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Ki-67 Antigen / metabolism. Papillomavirus Infections / complications. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184667.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Ki-67 Antigen
  •  go-up   go-down


13. Goh MS, Magee J, Chong AH: Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae. Australas J Dermatol; 2005 Nov;46(4):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae.
  • Additionally, there was keratosis pilaris on the cheeks, eyebrows and thighs.
  • With clinical correlation, the diagnosis of keratosis follicularis spinulosa decalvans and concurrent acne keloidalis nuchae was made.
  • The association of keratosis follicularis spinulosa decalvans with acne keloidalis nuchae has not previously been described.
  • [MeSH-major] Acne Keloid / diagnosis. Acne Keloid / etiology. Darier Disease / complications. Darier Disease / diagnosis. Scalp Dermatoses / diagnosis. Scalp Dermatoses / etiology


14. Jeffries ML, Aleck KA, Bernert RA, Hansen RC: Eccrine squamous metaplasia and periadnexal granulomas: new cutaneous histopathologic findings in cardiofaciocutaneous syndrome. Pediatr Dermatol; 2010 May-Jun;27(3):274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiofaciocutaneous syndrome is a rare genetic disorder characterized by dysmorphic facial features and neurologic, cardiac, ophthalmologic, and dermatologic findings.
  • Previously reported skin and hair findings in cardiofaciocutaneous syndrome include sparse, slow-growing curly hair, atopic dermatitis, ichthyosis, follicular hyperkeratosis, and keratosis pilaris.

  • Genetic Alliance. consumer health - Cardiofaciocutaneous Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. Clobetasol .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804494.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Pregnadienediols; 04201GDN4R / Mometasone Furoate; 7KYV510875 / pimecrolimus; ADN79D536H / Clobetasol; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; WI4X0X7BPJ / Hydrocortisone; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


15. Henning JS, Firoz BF: Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq. J Drugs Dermatol; 2010 Mar;9(3):210-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq.
  • This paper outlines the prevalence of skin disease among deployed service men and women in Operation Iraqi Freedom.
  • Actinic keratosis comprised 5% of the total visits (n=129).
  • CONCLUSION: This is the largest publication of the prevalence of skin disease in an exclusively dermatologic clinic in a combat setting.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232580.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. D'Addario S, Carrington PR: Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses. Acta Derm Venereol; 2006;86(4):366-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses.
  • [MeSH-major] Adjuvants, Immunologic / adverse effects. Aminoquinolines / adverse effects. Carcinoma, Squamous Cell / chemically induced. Keratoacanthoma / chemically induced. Keratosis / drug therapy. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874431.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


17. Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, McLean WH, Cordell HJ, Reynolds NJ: Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. Br J Dermatol; 2009 Oct;161(4):884-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Summating skin features known to be associated with FLG null mutations (ichthyosis, keratosis pilaris, palmar hyperlinearity and flexural eczema) showed a penetrance of 100% in children with two FLG mutations, 87.8% in children with one FLG mutation and 46.5% in wild-type individuals (P < 0.0001, Fisher exact test).
  • [MeSH-minor] Child. Dermatitis, Atopic / genetics. Female. Genetic Predisposition to Disease / genetics. Humans. Ichthyosis Vulgaris / genetics. Male. Phenotype. Prospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Eczema.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):901-10 [14638864.001]
  • [Cites] Br Med J. 1966 Apr 16;1(5493):947-50 [20790920.001]
  • [Cites] J Allergy Clin Immunol. 2004 May;113(5):832-6 [15131563.001]
  • [Cites] Br J Dermatol. 1985 Jun;112(6):679-85 [4005167.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):613-25 [8417356.001]
  • [Cites] Acta Derm Venereol. 1999 Sep;79(5):356-9 [10494710.001]
  • [Cites] Hum Mol Genet. 2005 Jan 15;14(2):335-46 [15590704.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):56-65 [15619623.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40 [15803139.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):1071-4 [15854050.001]
  • [Cites] Exp Dermatol. 2005 Oct;14(10):719-26 [16176279.001]
  • [Cites] Arch Dermatol Res. 2005 Dec;297(6):235-41 [16261374.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):337-42 [16444271.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):441-6 [16550169.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1770-5 [16810297.001]
  • [Cites] J Invest Dermatol. 2007 Mar;127(3):564-7 [16990802.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):173-82 [17403930.001]
  • [Cites] Nat Genet. 2007 May;39(5):650-4 [17417636.001]
  • [Cites] Nat Cell Biol. 2007 Jun;9(6):666-74 [17515931.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1667-72 [17301831.001]
  • [Cites] J Allergy Clin Immunol. 2007 Jul;120(1):150-5 [17512043.001]
  • [Cites] Br J Dermatol. 2007 Oct;157(4):645-8 [17714568.001]
  • [Cites] Acta Derm Venereol. 2007;87(6):499-505 [17989887.001]
  • [Cites] Pharmacogenomics. 2008 Apr;9(4):399-413 [18384254.001]
  • [Cites] J Allergy Clin Immunol. 2008 Apr;121(4):940-46.e3 [18313126.001]
  • [Cites] J Allergy Clin Immunol. 2008 Apr;121(4):872-7.e9 [18325573.001]
  • [Cites] J Allergy Clin Immunol. 2008 May;121(5):1294-5; author reply 1295-6 [18395783.001]
  • [Cites] J Allergy Clin Immunol. 2008 May;121(5):1203-1209.e1 [18396323.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1430-5 [18049447.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1591-4 [18094728.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1436-41 [18200065.001]
  • [Cites] J Invest Dermatol. 2008 Jul;128(7):1669-75 [18239616.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2117-9 [18305568.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):406-10 [18769192.001]
  • [Cites] J Allergy Clin Immunol. 2008 Oct;122(4):689-93 [18774165.001]
  • [Cites] J Invest Dermatol. 2009 Mar;129(3):543-52 [19209157.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1042-5 [18987673.001]
  • [Cites] Dermatol Ther. 2004;17 Suppl 1:43-8 [14728698.001]
  • (PMID = 19681860.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 074524; United Kingdom / Medical Research Council / / G0700314; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / filaggrin
  • [Other-IDs] NLM/ PMC2883069
  •  go-up   go-down


18. Kim C, Fangman W: Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma. Dermatol Online J; 2007;13(1):7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma.
  • A diagnosis of keratosis follicularis was made, which has been treated with isotretinoin.
  • Palmoplantar lesions of keratosis follicularis have been described as discrete, punctate keratoses, hyperkeratotic papules, small pits, or keratin-filled depressions.
  • This patient has an unusual palmoplantar keratoderma in association with keratosis follicularis.
  • [MeSH-major] Darier Disease / complications. Keratoderma, Palmoplantar / etiology
  • [MeSH-minor] Administration, Oral. Adult. Biopsy. Diagnosis, Differential. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Isotretinoin / administration & dosage. Keratolytic Agents / administration & dosage. Ointment Bases / administration & dosage. Petrolatum / administration & dosage. Salicylic Acid / administration & dosage. Skin / pathology

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Palmoplantar Keratoderma.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. SALICYLIC ACID .
  • Hazardous Substances Data Bank. PETROLATUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511940.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratolytic Agents; 0 / Ointment Bases; 8009-03-8 / Petrolatum; EH28UP18IF / Isotretinoin; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down


19. Ibrahim SF, Brown MD: Actinic keratoses: a comprehensive update. J Clin Aesthet Dermatol; 2009 Jul;2(7):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: a comprehensive update.
  • Actinic keratoses are common intra-epidermal neoplasms that lie on a continuum with squamous cell carcinoma.
  • Tightly linked to ultraviolet irradiation, they occur in areas of chronic sun exposure, and early treatment of these lesions may prevent their progression to invasive disease.
  • Several previously experimental options, such as imiquimod and photodynamic therapy, have become incorporated as first-line options for the treatment of actinic keratoses, while combination treatment strategies have been gaining in popularity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1031-3 [2064403.001]
  • [Cites] Br J Dermatol. 1986 Dec;115(6):649-55 [3801305.001]
  • [Cites] Dermatol Surg. 1996 Jan;22(1):17-21 [8556252.001]
  • [Cites] Dermatol Surg. 1997 Mar;23(3):191-6 [9145962.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4 [10607353.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):22-9 [12353677.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • [Cites] Arch Dermatol. 2004 Jul;140(7):813-6 [15262691.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Drugs Dermatol. 2005 May-Jun;4(3):296-301 [15898284.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Arch Dermatol Res. 2005 Nov;297(5):185-9 [16235081.001]
  • [Cites] Dermatol Surg. 2006 Feb;32(2):261-7 [16442048.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1251-5 [16557235.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):9-22 [16792746.001]
  • [Cites] Lasers Surg Med. 2006 Sep;38(8):731-9 [16912977.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Dermatol Surg. 2006 Oct;32(10):1261-5 [17034376.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jun;65(6):1135-9 [17517297.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:34-40 [18067630.001]
  • [Cites] J Cutan Med Surg. 2008 May-Jun;12(3):97-101 [18544290.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):669-73 [18664159.001]
  • [Cites] J Am Acad Dermatol. 2009 Jan;60(1):59-62 [18937999.001]
  • (PMID = 20729970.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2924136
  •  go-up   go-down


20. Petit A: [Actinic keratoses are still actinic keratoses]. Ann Dermatol Venereol; 2008 Feb;135(2):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratoses are still actinic keratoses].
  • [MeSH-major] Keratosis / diagnosis. Photosensitivity Disorders / diagnosis
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Disease Progression. Humans. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Terminology as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342088.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Editorial
  • [Publication-country] France
  •  go-up   go-down


21. Pavlović MD, Milenković T, Dinić M, Misović M, Daković D, Todorović S, Daković Z, Zecevi RD, Doder R: The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care; 2007 Aug;30(8):1964-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to assess the prevalence of cutaneous disorders and their relation to disease duration, metabolic control, and microvascular complications in children and adolescents with type 1 diabetes.
  • RESULTS: One hundred forty-two (68%) type 1 diabetic patients had at least one cutaneous disorder vs. 52 (26.5%) control subjects (P < 0.01).
  • Keratosis pilaris affected 12% of our patients vs. 1.5% of control subjects.
  • Significant association was also found between acquired ichthyosis and keratosis pilaris (1.53 [1.09-1.79]; P < 0.001).
  • CONCLUSIONS: Cutaneous manifestations are common in type 1 diabetic patients, and some of them, like acquired ichthyosis and keratosis pilaris, develop early in the course of the disease.
  • Diabetic hand and rubeosis faciei are related to disease duration.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519431.001).
  • [ISSN] 1935-5548
  • [Journal-full-title] Diabetes care
  • [ISO-abbreviation] Diabetes Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Skiveren J, Haedersdal M, Philipsen PA, Wiegell SR, Wulf HC: Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol; 2006;86(5):409-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study involved 28 patients with actinic keratoses or basal cell carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Double-Blind Method. Gels. Humans. Keratosis / drug therapy. Middle Aged. Photosensitivity Disorders / drug therapy. Receptors, Opioid / physiology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955184.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Gels; 0 / Receptors, Opioid; 0 / methyl 5-aminolevulinate; 76I7G6D29C / Morphine; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Lee WJ, Park GH, Lee MW, Choi JH, Moon KC, Koh JK: Keratosis follicularis and dermatomyositis: is there a common pathogenesis? J Eur Acad Dermatol Venereol; 2009 Aug;23(8):977-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis and dermatomyositis: is there a common pathogenesis?
  • [MeSH-major] Darier Disease / etiology. Dermatomyositis / etiology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210696.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Bartels P, Yozwiak M, Einspahr J, Saboda K, Liu Y, Brooks C, Bartels H, Alberts DS: Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. Anal Quant Cytol Histol; 2009 Dec;31(6):355-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry.
  • OBJECTIVE: To determine whether low-dose topical applications of difluoromethylornithine (DFMO) with or without Triamcinolone (Fougena, Melville, New York, U.S.A.) to moderately sun-damaged skin with actinic skin keratoses are efficacious.
  • Participant eligibility included evidence of at least 2 actinic keratoses on each posterolateral forearm as well as moderate to severe evidence of sun-damaged skin, as evaluated by a board certified dermatologist.
  • Two specific measures of end point evaluation were computed, including the percentage of nuclei with high values of nuclear abnormality and the reduction of the percentage of nuclei assigned by a discriminant function to the baseline data set.
  • All 3 active interventions, including low-dose topical DFMO, topical Triamcinolone and topical DFMO + Triamcinolone, led to statistically significant reductions of both the number of nuclei with high nuclear abnormality as well as the number of nuclei assigned to the baseline data set.
  • CONCLUSION: The low-dose, topical drug interventions were all effective in reducing skin biopsy nuclear abnormality by a statistically significant 15-20%, whereas there was no evidence of a double placebo effect by karyometric assessment.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIAMCINOLONE .
  • Hazardous Substances Data Bank. Eflornithine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Apr;57(4 Suppl 1):129-31 [11295610.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):300-12 [11531145.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Aug;24(4):185-97 [12199319.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1875-80 [15041701.001]
  • [Cites] Cytometry. 1986 Sep;7(5):467-74 [3757694.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):407-16 [9801759.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Apr;29(2):63-70 [17484269.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1689-95 [18583468.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):316-22 [19160696.001]
  • [Cites] Anal Quant Cytol Histol. 2009 Feb;31(1):17-25 [19320189.001]
  • (PMID = 20698351.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Lipids; 0 / Ointment Bases; 1ZK20VI6TY / Triamcinolone; 8036-49-5 / eucerin; ZQN1G5V6SR / Eflornithine
  • [Other-IDs] NLM/ NIHMS586544; NLM/ PMC4038432
  •  go-up   go-down


25. Garcia Carmona FJ, Pascual Huerta J, Hernandez Toledo J: Plantar epidermoid inclusion cyst as a possible cause of intractable plantar keratosis lesions. J Am Podiatr Med Assoc; 2009 Mar-Apr;99(2):148-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plantar epidermoid inclusion cyst as a possible cause of intractable plantar keratosis lesions.
  • Inclusion cysts are benign lesions that appear as a consequence of traumatic inclusion of epidermal cells into the dermis.
  • We report a case of a 36-year-old woman with an intractable plantar keratosis lesion under the third metatarsal head of 3 years' duration.
  • It was surgically excised, and pathology confirmed the diagnosis of a plantar epidermoid cyst.
  • This case should alert the clinician about the existence of keratotic lesions in the metatarsal heads commonly diagnosed and treated as intractable plantar keratosis, although they are not directly derived from metatarsal overload.
  • [MeSH-major] Epidermal Cyst / diagnosis. Epidermal Cyst / surgery. Foot Diseases / diagnosis. Foot Diseases / surgery. Keratoderma, Palmoplantar / etiology

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299353.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hossain MK, Khan MM, Alam MA, Chowdhury AK, Delwar Hossain M, Feroze Ahmed M, Kobayashi K, Sakauchi F, Mori M: Manifestation of arsenicosis patients and factors determining the duration of arsenic symptoms in Bangladesh. Toxicol Appl Pharmacol; 2005 Oct 1;208(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanosis was common (97%) among them but about two-thirds (68.7%) of the patients were suffering from keratosis.
  • Keratosis was also significantly associated with older age (P=0.022), shallower tubewell (P<0.001), complication of conjunctivitis (P<0.001), bronchitis (P<0.001), loss of appetite (P<0.001), and wasting (P<0.001).
  • Multivariate odds ratio (OR) and 95% confidence interval (CI) indicated that keratosis (OR=2.00; 95% CI: 1.56-2.56) was significantly associated with longer duration of arsenic symptoms; loss of appetite (OR=1.40; 95% CI: 1.12-1.74) was a significant complication for longer duration.
  • [MeSH-major] Arsenic Poisoning / complications. Keratosis / etiology. Melanosis / etiology
  • [MeSH-minor] Adult. Age Distribution. Arsenic / analysis. Bangladesh / epidemiology. Chronic Disease. Conjunctivitis / diagnosis. Conjunctivitis / epidemiology. Conjunctivitis / etiology. Female. Health Surveys. Humans. Male. Middle Aged. Odds Ratio. Sex Distribution. Surveys and Questionnaires. Time Factors. Water Pollution / analysis. Water Supply / standards. Water Supply / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Arsenic.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164963.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] N712M78A8G / Arsenic
  •  go-up   go-down


27. Martínez-García S, del Boz-González J, Martín-González T, Samaniego-González E, Crespo-Erchiga V: [Teledermatology. Review of 917 teleconsults]. Actas Dermosifiliogr; 2007 Jun;98(5):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The majority of the 917 teleconsults performed were for benign lesions, notably seborrheic keratosis in 201 cases; among malignant lesions actinic keratosis appeared in 161 cases and melanoma was diagnosed in 5 cases.
  • Fifty-eight percent of teleconsults have been arranged for a face-to-face consult in order to perform adequate treatment, in 90 % of cases, or to confirm diagnosis or carry out complementary exams, in 10 % of cases.
  • CONCLUSION: The image is the gold standard for dermatological diagnosis.
  • [MeSH-major] Skin Diseases / diagnosis. Telemedicine

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555674.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


28. Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C: Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol; 2006 Dec;45(12):1464-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod.
  • [MeSH-major] Aminoquinolines / adverse effects. Keratosis / drug therapy. Psoriasis / chemically induced

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184267.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


29. Angell-Petersen E, Sørensen R, Warloe T, Soler AM, Moan J, Peng Q, Giercksky KE: Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol; 2006 Feb;126(2):265-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate.
  • Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK).
  • MAL induces endogenous porphyrins, which act as photosensitizers.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / biosynthesis. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374471.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


30. Krouse RS, Alberts DS, Prasad AR, Yozwiak M, Bartels HG, Liu Y, Bartels PH: Progression of skin lesions from normal skin to squamous cell carcinoma. Anal Quant Cytol Histol; 2009 Feb;31(1):17-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Biopsies were taken from 140 cases with sun-exposed but histopathologically normal skin, from 20 cases visually assessed as pre-actinic keratosis (pre-AK) or early AK, from 30 cases of AK, and from 21 cases of SCC.
  • Using karyometry, no significant differences could be substantiated between nuclei collected from early AK sites and AK lesions.
  • A larger group (approximately 66.7% of cases) had characteristics similar to AK.
  • CONCLUSION: Karyometric assessment can provide a numeric measure of progression for sun damage and of the deviation from normal in both AK and SCC lesions.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Cancer Conf. 1970;6:471-88 [5458117.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Br J Dermatol. 1990 Apr;122 Suppl 35:49-54 [2186785.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1031-3 [2064403.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):316-22 [19160696.001]
  • [Cites] Dermatol Surg. 1995 Feb;21(2):184 [7894943.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):557-60 [7577583.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):920-3 [9041154.001]
  • [Cites] Drugs Aging. 1997 Sep;11(3):186-205 [9303279.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Feb;20(1):21-8 [9513688.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):397-406 [9801758.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002 [15598753.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):353-61 [14714302.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):300-12 [11531145.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • (PMID = 19320189.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P01 CA027502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin
  • [Other-IDs] NLM/ NIHMS584930; NLM/ PMC4061044
  •  go-up   go-down


31. Maharjan M, Shrestha RR, Ahmad SA, Watanabe C, Ohtsuka R: Prevalence of arsenicosis in terai, Nepal. J Health Popul Nutr; 2006 Jun;24(2):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin manifestations, such as melanosis and keratosis, were the common symptoms of arsenicosis.
  • Most patients were identified in the early or mild stage of the disease.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Epidemiologic Studies. Female. Geography. Humans. Keratosis / chemically induced. Male. Melanosis / chemically induced. Middle Aged. Nepal / epidemiology. Population Surveillance. Prevalence. Risk Factors. Severity of Illness Index. Sex Distribution. Tropical Climate. Water Supply / analysis. Water Supply / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Arsenic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195566.001).
  • [ISSN] 1606-0997
  • [Journal-full-title] Journal of health, population, and nutrition
  • [ISO-abbreviation] J Health Popul Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


32. Scott IS, Odell E, Chatrath P, Morris LS, Davies RJ, Vowler SL, Laskey RA, Coleman N: A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia. Br J Cancer; 2006 Apr 24;94(8):1170-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical examination of 66 oral tissue samples showed a greater frequency of Mcm-2 expression in surface layers of moderate/severe dysplasia and SCC compared to benign keratosis/mild dysplasia.
  • Conventional smears included 23 from normal mucosa, benign proliferative disease and mild dysplasia, all of which were MCM negative.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / analysis. Mouth Neoplasms / diagnosis. Nuclear Proteins / analysis. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2000 Mar;6(2):65-74 [10702782.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):135-41 [15660109.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):198-207 [11836525.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1917-9 [12057556.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] J Pathol. 2003 Oct;201(2):187-97 [14517835.001]
  • [Cites] Br J Cancer. 1971 Mar;25(1):21-4 [5581297.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):861-72 [8631307.001]
  • [Cites] Bioessays. 1996 Mar;18(3):183-90 [8867732.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):260-4 [9633535.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):113-36 [9689912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):187-93 [11437923.001]
  • (PMID = 16622441.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359878
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2361243
  •  go-up   go-down


33. Dixon A: Rare skin cancers in general practice. Aust Fam Physician; 2007 Mar;36(3):141-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mr LA has long been troubled with actinic damage to his skin, especially his face.
  • He has had many squamous cell carcinomas (SCCs) removed and many solar keratoses managed.
  • On this occasion Mr LA had two actinic lesions on his left cheek that failed to respond to cryotherapy.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Australia. Family Health. Family Practice. Humans. Male. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Radiation-Induced / therapy. Sarcoma / diagnosis. Sarcoma / therapy. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Gland Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339977.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Smith K, Hamza S, Germain M, Skelton H: Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatol Surg; 2007 Dec;33(12):1419-28; discussion 1428-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Pre- and posttherapy biopsies of 12 patients with histories of actinic keratoses were evaluated with routine histology and immunohistochemical stains including p53, p63, proliferating cell nuclear antigen (PCNA), c-kit, and Factor XIIIa.
  • RESULTS: After IMI therapy there was less compact hyperkeratosis, a more uniform rete ridge pattern with a more ordered proliferation of the epidermis, and a decrease in sun-damaged melanocytes.
  • The papillary dermis showed a more uniform cellularity, and there was increased cellularity within the area of solar elastosis.
  • CONCLUSION: These morphologic and immunohistochemical patterns may explain some of the improvement in overall skin appearance after IMI therapy and may be related to the spectrum of signaling pathways induced by the imidazoquinolines.
  • [MeSH-minor] Biopsy. Female. Humans. Immunohistochemistry. Keratosis / drug therapy. Keratosis / pathology. Male. Middle Aged. Photosensitivity Disorders / drug therapy. Photosensitivity Disorders / pathology. Pilot Projects. Rejuvenation. Signal Transduction. Skin Diseases / drug therapy. Skin Diseases / pathology. Sunlight / adverse effects


35. Baptista J, Martinez C, Leite L, Cochito M: Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Topical photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) was first described by Kennedy et al. in 1990; currently, accumulated evidence shows that topical PDT is effective in the treatment of actinic keratoses, Bowen's disease and superficial basal cell carcinoma, being potentially advantageous where size, anatomical location or number of lesions limit the efficacy and/or the acceptability of conventional therapies.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836497.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


36. Ferrara G, Zalaudek I, Cabo H, Soyer HP, Argenziano G: Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology? Clin Exp Dermatol; 2005 Sep;30(5):586-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology?
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Exp Dermatol. 2004 Mar;29(2):199-200 [14987284.001]
  • (PMID = 16045704.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


37. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C: Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol; 2010 Mar;24(3):258-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
  • BACKGROUND: Actinic keratoses (AKs) are frequently diagnosed in dermatological patients.
  • OBJECTIVES: We investigated the effect of topical 3.0% diclofenac in 2.5% hyaluronic acid gel on AK.
  • Specimens were evaluated for histological type of AKs using the AK classification scheme suggested by Röwert-Huber et al. [(early) in situ squamous cell carcinoma type AK Grade I-III], number of mitoses per high-power field and expression of immunohistological markers.
  • A significant (P<0.001) downgrading of AK grade was observed.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Diclofenac / administration & dosage. Hyaluronic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Precancerous Conditions / prevention & control. Skin / pathology. Skin Neoplasms / prevention & control
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Disease Progression. Female. Follow-Up Studies. Gels. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709346.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


38. Haake DL, Minni JP, Nowak M, Abenoza P, Nousari CH: Reticulated acanthoma with sebaceous differentiation. Lack of association with Muir-Torre syndrome. Am J Dermatopathol; 2009 Jun;31(4):391-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hereby report a case of a reticulated acanthoma with sebaceous differentiation (RASD), a rare and often mislabeled benign lesion that is characterized by epidermal acanthosis and clusters of sebocytes in a reticulated seborrheic keratosis-like pattern.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461247.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Cohen JL: Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2010 Jun;3(6):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.
  • Actinic keratosis is responsible for more than eight million visits to dermatologists and primary care physicians annually.
  • Actinic keratosis, the result of chronic sun damage to the skin, is closely linked to nonmelanoma skin cancer, both histologically and pathophysiologically.
  • Clinical evidence shows that not only does actinic keratosis have the potential to progress and transform into nonmelanoma skin cancer, but it also may in fact be an early stage of cancer.
  • The treatment of actinic keratosis is evolving from a "treat-as-you-go" strategy to a more preventive approach to curtail the potential emergence of nonmelanoma skin cancer.
  • As the interrelationship between actinic keratosis and nonmelanoma skin cancer, squamous cell carcinoma, and basal cell carcinoma continues to strengthen, treating actinic keratosis as part of a preventive strategy to reduce nonmelanoma skin cancer is coming to the forefront.
  • The following review of the relationship between actinic keratosis and nonmelanoma skin cancer discusses the rationale for early actinic keratosis treatment to prevent or reduce nonmelanoma skin cancer occurrence.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2004 Dec;74(6 Suppl):9-17 [15666897.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):8-13 [12353680.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] J Cutan Med Surg. 2002 May-Jun;6(3):207-9 [11951126.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85 [11880204.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):149-56 [10620131.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):171-5 [19863513.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1248-55 [18403589.001]
  • [Cites] Dermatol Surg. 2008 Jan;34(1):9-13; discussion 13-4 [18053057.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Dermatol Surg. 2007 Sep;33(9):1099-101 [17760601.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):976-82 [16924046.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] J Fam Pract. 2006 May;55(5):suppl 1-8 [16672155.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Clin Transplant. 2005 Dec;19(6):726-34 [16313317.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):60-7 [15655143.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):28-33 [15842610.001]
  • [Cites] Cutis. 1999 Jun;63(6):348 [10388958.001]
  • [Cites] Int J Dermatol. 1998 Sep;37(9):677-81 [9762818.001]
  • [Cites] J Eur Acad Dermatol Venereol. 1998 Jan;10(1):42-7 [9552756.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):920-3 [9041154.001]
  • [Cites] J Invest Dermatol. 1994 Oct;103(4):461-8 [7930668.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):829-35 [3534022.001]
  • [Cites] Br J Dermatol. 1986 Dec;115(6):649-55 [3801305.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):189-96 [15262304.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):759-65 [15681519.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 2:3-6 [14578092.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • (PMID = 20725550.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2921751
  •  go-up   go-down


40. Slobodin G, Lurie M, Munichor M, Kovalev J, Rosner I: Gottron's papules-like eruption developing under hydroxyurea therapy. Rheumatol Int; 2006 Jun;26(8):768-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin biopsy was compatible with seborrheic keratosis.
  • [MeSH-major] Dermatomyositis / diagnosis. Hydroxyurea / adverse effects. Hydroxyurea / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1975 Feb 13;292(7):344-7 [1090839.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 2):316-9 [8698915.001]
  • [Cites] Br J Rheumatol. 1998 Oct;37(10):1135-6 [9825757.001]
  • [Cites] Postgrad Med J. 1996 Nov;72(853):694 [8944218.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):862-5 [7779132.001]
  • [Cites] Clin Immunol Immunopathol. 1992 Oct;65(1):70-4 [1382910.001]
  • [Cites] Dermatol Clin. 2002 Jul;20(3):387-408 [12170874.001]
  • [Cites] J Rheumatol. 1987 Apr;14(2):397-8 [3599016.001]
  • [Cites] J Cutan Pathol. 1985 Oct;12(5):389-94 [4056162.001]
  • [Cites] Am J Dermatopathol. 1983 Jun;5(3):241-3 [6353971.001]
  • [Cites] Ann Rheum Dis. 1977 Feb;36(1):94-5 [843119.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):439-41 [12637927.001]
  • [Cites] J Child Neurol. 1998 Nov;13(11):577-80 [9853654.001]
  • [Cites] Acta Derm Venereol. 1997 Nov;77(6):490 [9394998.001]
  • [Cites] Br J Rheumatol. 1994 Feb;33(2):199 [8162495.001]
  • [Cites] Clin Exp Dermatol. 2005 Mar;30(2):191-2 [15725256.001]
  • [Cites] Clin Exp Dermatol. 2001 Mar;26(2):141-8 [11298103.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):415-6 [12563706.001]
  • (PMID = 16583187.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


41. Cushing SL, MacDonald L, Propst EJ, Sharma A, Stockley T, Blaser SL, James AL, Papsin BC: Successful cochlear implantation in a child with Keratosis, Icthiosis and Deafness (KID) Syndrome and Dandy-Walker malformation. Int J Pediatr Otorhinolaryngol; 2008 May;72(5):693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cochlear implantation in a child with Keratosis, Icthiosis and Deafness (KID) Syndrome and Dandy-Walker malformation.
  • Keratosis, Icthiosis, and Deafness (KID) Syndrome is a rare congenital disorder associated with dominant connexin 26 mutations, affecting epidermis, corneal epithelium, and inner ear.
  • [MeSH-major] Cochlear Implantation. Dandy-Walker Syndrome / complications. Hearing Loss, Sensorineural / therapy. Ichthyosis / complications. Keratosis / complications


42. Bchetnia M, Benmously R, Ben Brick AS, Charfeddine C, Ben Ameur Y, Fajraoui M, Debbiche A, Ben Ayed M, Mokni M, Fenniche S, Mokhtar I, Abdelhak S: New mutations of Darier disease in Tunisian patients. Arch Dermatol Res; 2009 Sep;301(8):615-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New mutations of Darier disease in Tunisian patients.
  • Darier's disease (DD, MIM 124200) also known as Darier-White disease and keratosis follicularis, is a rare autosomal dominant skin disorder characterized by warty papules and plaques in the seborrheic area (central trunk, flexures, scalp, and forehead).
  • Pathogenic mutations in the ATP2A2 gene encoding the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase (SERCA) 2 gene underlie the disease.
  • Our findings provide further evidence for the genetic heterogeneity of DD in Tunisia and that most mutations involved in this disease are family specific.
  • [MeSH-major] Darier Disease / metabolism. Mutation. Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics

  • Genetic Alliance. consumer health - Darier Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488774.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.6.3.8 / ATP2A2 protein, human; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases
  •  go-up   go-down


43. Mitsuhashi Y, Kawaguchi M, Hozumi Y, Kondo S: Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol; 2005 Jun;32(6):420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis.
  • Senile wart or seborrheic keratosis is a benign tumor which occurs mainly in the elderly.
  • We treated senile warts with topical vitamin D3 ointments (tacalcitol, calcipotriol or maxacalcitol).
  • An organ culture experiment using senile wart as a material with several concentrations of tacalcitol revealed that tacalcitol induced apoptosis in the tissue.
  • Vitamin D3 may affect senile warts by inducing apoptosis.
  • Clearance of senile warts, especially on exposed areas without pain, may improve the quality of life (QOL) of the elderly.
  • [MeSH-major] Cholecalciferol / therapeutic use. Keratosis, Seborrheic / drug therapy. Keratosis, Seborrheic / pathology

  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043912.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


44. Hadley G, Derry S, Moore RA: Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol; 2006 Jun;126(6):1251-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod for actinic keratosis: systematic review and meta-analysis.
  • Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier imiquimod was assessed using published randomized-controlled trials.
  • Complete clearance occurred in 50% of patients treated with imiquimod, compared to 5% treated with vehicle, and the number needed to treat (NNT) for one patient to have their keratosis completely cleared after 12-16 weeks was 2.2 (95% confidence interval 2.0-2.5).
  • Imiquimod 5% cream was effective in the treatment of AK, preventing potential development of squamous cell carcinoma.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557235.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  • [Number-of-references] 27
  •  go-up   go-down


45. Yoon TY, Kim HJ, Kim JW, Kim MK, Lee JY: Bowen's disease concealed by purpura. J Dermatol; 2007 Jan;34(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease concealed by purpura.
  • Bowen's disease (BD) is a squamous cell carcinoma in situ characterized by a well-demarcated scaly erythematous thin plaque with an irregular outline.
  • Clinically, BD is frequently misdiagnosed as superficial basal cell carcinoma, patches of dermatitis, psoriasis, lichen planus, actinic keratosis, benign lichenoid keratosis, irritated seborrheic keratosis, viral warts, amelanotic melanoma or melanoma.
  • However, angiosarcoma has not usually been mentioned in the differential diagnosis of BD before.
  • [MeSH-major] Bowen's Disease / complications. Purpura / complications. Scalp. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204105.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Bongiorno MR, Aricò M: Progressive symmetric erythro-keratosis associated with oligodontia, severe caries, disturbed hair growth and ectopic nail: a new syndrome? Dermatology; 2008;217(4):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive symmetric erythro-keratosis associated with oligodontia, severe caries, disturbed hair growth and ectopic nail: a new syndrome?
  • Histological examination showed marked hyperkeratosis with parakeratosis, and a thickened granular cell layer, mild acanthosis and slight lymphocytic infiltration surrounding the papillary blood vessels, compatible with a diagnosis of progressive symmetrical erythro-keratosis.
  • Progressive symmetric erythro-keratosis has so far been described as a non-syndromic skin disorder, which is why our patient's multisystem birth defect may represent a new entity.
  • [MeSH-major] Abnormalities, Multiple / pathology. Anodontia / pathology. Dental Caries. Hair / pathology. Hyperkeratosis, Epidermolytic / pathology. Nails / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Syndrome

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18799882.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Choi KH, Kim GM, Kim SY: The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression? Cancer Res Treat; 2010 Jun;42(2):107-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression?
  • PURPOSE: Actinic keratosis (AK) is an incipient form of cutaneous squamous cell carcinoma (SCC).
  • We determined if the pattern of expression of keratin-14 (K14) is a factor for tumor progression in AK and SCC.
  • Among the 16 patients, 4 were diagnosed with both SCC and AK at the same site, but AK developed first and SCC developed subsequently.
  • Thus, SCC may have evolved from AK.
  • The other 12 patients were only diagnosed with AK.
  • RESULTS: In all of the AK and SCC tissues, basement membranes showed positive staining for K14.
  • However, strong reactivities were shown in the spinous and granular layers and focuses of dermal invasion in the SCC tissues developed from AK.
  • Two and 3 of the 12 AK cases had moderately positive reactions for K14 in the spinous and granular layers, respectively.
  • Two of the 12 AK cases had weak-to-moderate positive reactions in the basal, spinous, and horny layers for p16(INK4a).
  • CONCLUSION: The results of our study advance our understanding of the pathogenesis of SCC developing from AK.
  • The results also indicate a differential role in the control of K14 in normal epithelia, AK, and SCC.
  • K14 expression in the spinous and granular layers may be a prognostic factor for tumor progression of AK.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 1999 Jul;17(3):667-89, x [10410866.001]
  • [Cites] J Clin Pathol. 1997 Dec;50(12):1032-3 [9516889.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):26-30 [9036865.001]
  • [Cites] J Oral Pathol Med. 1996 Jul;25(6):293-301 [8887072.001]
  • [Cites] Growth Factors. 1995;12(2):87-97 [8679251.001]
  • [Cites] Dermatol Surg. 1995 Feb;21(2):184 [7894943.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Sep;30B(5):305-11 [7535610.001]
  • [Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Dermatol Surg Oncol. 1985 May;11(5):518-22 [3998264.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):189-96 [15262304.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1006-12 [14632806.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):223-8 [11531783.001]
  • [Cites] Histopathology. 2001 Jul;39(1):9-16 [11454039.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] South Med J. 2000 Jul;93(7):650-5 [10923948.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4 [10607353.001]
  • (PMID = 20622965.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901083
  • [Keywords] NOTNLM ; Actinic / Carcinoma / Keratin-14 / Keratosis / Squamous cell / p16INK4a
  •  go-up   go-down


48. Ortonne JP, Queille-Roussel C, Duteil L: 3% diclofenac in 2.5% hyaluronic acid (Solaraze) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens. Eur J Dermatol; 2006 Jul-Aug;16(4):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical treatment with 3% diclofenac in 2.5% hyaluronic acid (Solaraze) has been extensively documented for the treatment of actinic keratoses (AK).
  • Since sun protection is a vital part of AK management, two Phase IV studies were carried out to investigate the phototoxicity and photosensitisation potential of 3% diclofenac in 2.5% hyaluronic acid in combination with sunscreens.

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935795.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drug Combinations; 0 / Sunscreening Agents; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


49. Badura-Stronka M, Jamsheer A, Materna-Kiryluk A, Sowińska A, Kiryluk K, Budny B, Latos-Bieleńska A: A novel nonsense mutation in CUL4B gene in three brothers with X-linked mental retardation syndrome. Clin Genet; 2010 Feb;77(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the symptoms, we made a clinical diagnosis of Cabezas syndrome, which was subsequently confirmed by identification of a novel nonsense mutation (c.2107A-->T, p.703K-->X) in exon 18 of the CUL4B gene.
  • In addition to previously described symptoms, syndactyly of the second and third toes and skin manifestations (hyperhydrosis and keratosis pilaris) were present in our cases.


50. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A: Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum; 2005 Aug;52(8):2513-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe 5 patients in whom psoriasiform skin lesions developed 6-9 months after the initiation of anti-TNF therapy for longstanding, seropositive rheumatoid arthritis (etanercept or adalimumab), typical ankylosing spondylitis (infliximab), and Adamantiades-Behçet's disease (infliximab).
  • In all 5 patients, the underlying disease had responded well to anti-TNF therapy.
  • In 3 patients there was nail involvement with onycholysis, yellow discoloration, and subungual keratosis.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052599.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


51. Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P: Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol; 2010 Jul 1;19(7):641-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
  • BACKGROUND: During treatment of actinic keratosis (AK) lesions with imiquimod sub-clinical lesions often become visible.
  • OBJECTIVE: The aim of this pilot study was to compare two techniques, cross polarized light photography (CPL) and fluorescence diagnosis (FD) using methyllevulinic acid and illumination with Wood's lamp for their ability to detect sub-clinical lesions.
  • METHODOLOGY: Twelve patients with at least five clinically visible AK lesions in a single contiguous 20 cm(2) area on the head were recruited.
  • Patients were assessed for baseline AK lesion counts (clinical and sub-clinical) at the screening visit and final counts at week 20.
  • RESULTS: The number of clinically observed AK lesions was significantly lower at week 12 and week 20 compared with baseline following imiquimod treatment versus vehicle.
  • CONCLUSION: The number of sub-clinical and clinical AK lesions detected during treatment with imiquimod can be better demonstrated using the methods of CPL and FD, but statistical significance was reached only using the CPL method.
  • However, results were encouraging and indicate that larger studies are needed to demonstrate the relevance of these two new methods for improved detection of clinical and especially sub-clinical AK lesions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Keratosis, Actinic / diagnosis. Keratosis, Actinic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201959.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Levulinic Acids; 0 / Photosensitizing Agents; 3Q95S830W6 / methyl levulinate; 99011-02-6 / imiquimod
  •  go-up   go-down


52. Saeed S, Sagatys E, Morgan MB: Acral keratosis with eosinophilic dermal deposits: a distinctive clinicopatholgic entity or colloid milium redux? J Cutan Pathol; 2006 Oct;33(10):679-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acral keratosis with eosinophilic dermal deposits: a distinctive clinicopatholgic entity or colloid milium redux?
  • AIMS: The differential diagnosis of acral keratoses is broad.
  • Encompassing a variety of infectious, heritable and degenerative disorders, emphasis upon the clinical setting and histologic subtlety are often required to arrive at the correct diagnosis.
  • Potential sources of the material and a discussion of the differential diagnosis follow.
  • [MeSH-major] Eosinophilia / pathology. Keratosis / pathology. Skin Diseases / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fingers / pathology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026520.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


53. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS: Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol; 2007 Jun;177(6):2347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It recently showed clinical efficacy against several benign and malignant skin lesions, including actinic keratosis and basal cell carcinoma.
  • Working primarily through the stimulation of a proinflammatory immune response, the mechanism of action of imiquimod may be similar to that through which bacillus Calmette-Guerin is thought to act.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Culture Techniques. Cell Survival / drug effects. Cytokines / metabolism. Disease Models, Animal. Humans. Mice. Toll-Like Receptor 7 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509356.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


54. Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N: 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol; 2006 Jul-Aug;82(4):994-1015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5-ALA-mediated photodynamic therapy (PDT) and fluorescence photodetection (FD) of neoplastic disease is probably one of the most selective cancer treatments currently known in oncology.
  • MAL is marketed under the trade name Metvix for the treatment of actinic keratosis and difficult-to-treat basal cell carcinoma.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542112.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 183
  •  go-up   go-down


55. Hafner C, Di Martino E, Pitt E, Stempfl T, Tomlinson D, Hartmann A, Landthaler M, Knowles M, Vogt T: FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res; 2010 Jul 15;316(12):2008-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FGFR3 mutations have recently been identified in several benign epidermal skin lesions such as seborrheic keratosis, epidermal nevus and solar lentigo.

  • Genetics Home Reference. consumer health - epidermal nevus.
  • Genetics Home Reference. consumer health - FGFR3 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420824.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


56. Bordbar A, Dias D, Cabral A, Beck S, Boon ME: Assessment of cell proliferation in benign, premalignant and malignant skin lesions. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A deeper understanding of the variance of epidermal cell proliferation may eventually increase the reproducibility of diagnostic classification.
  • A prospective study of 46 consecutive, unselected biopsies from benign (keratoacanthoma n=14), premalignant (actinic keratosis n=15 and Bowen disease n=10) and malignant (squamous cell carcinoma n=7) skin lesions was studied to assess the presence and extent of differences in expression of the proliferation marker Ki-67 using a monoclonal antibody directed against a c-DNA defined subsegment (MIB-1) and a noncross-linking, proprietary fixative BoonFix.
  • In actinic keratosis, MIB-1 expression, in addition to basal/suprabasal layers, extended to mid-zones of the epidermis.
  • An interesting feature in actinic keratosis as well as in Bowen disease was the expression of MIB-1 in the epithelium lining the hair follicles.
  • In Bowen disease, MIB-1 was observed throughout the full thickness of the epidermis, unequivocally separating this entity from others under study.
  • These results warrant further study of modulation of cell proliferation in actinic keratosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525640.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


57. Ferringer T, Rogers HC, Metcalf JS: Merkel cell carcinoma in situ. J Cutan Pathol; 2005 Feb;32(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal involvement is unusual and MCC limited to the epidermis is very rare.
  • An intraepidermal proliferation of small blue cells distributed in nests and single units at all levels of the epidermis was found within a solar keratosis and adjacent to an area of squamous cell carcinoma in situ.
  • [MeSH-minor] Aged. Diagnosis, Differential. Epidermis / metabolism. Epidermis / pathology. Epidermis / surgery. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606676.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Drukała J, Bobis S, Zabińska-Płazak E, Wojas-Pelc A: [Molecular basis of pigmentation disorders in skin diseases]. Przegl Lek; 2009;66(3):145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work we focused on molecular basis of pigmentation disorders in dermatological diseases that present clinically with hyperpigmentation (lentigo senilis, Riehl melanosis, seborrhoic keratosis, fibroma, café-au-lait patches melasma, atopic dermatitis) or hypopigmentation (vitiligo, albinism).
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperpigmentation / diagnosis. Hyperpigmentation / metabolism. Hypopigmentation / diagnosis. Hypopigmentation / metabolism. Melatonin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689040.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] JL5DK93RCL / Melatonin
  • [Number-of-references] 24
  •  go-up   go-down


59. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM: Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer; 2009 Jan;7(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
  • Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated.
  • The time to development of SCC or AK from the start of sorafenib was 9.3 months (median, 6.5 months; range, 0.9-43 months).
  • Ten of these 14 patients discontinued therapy with sorafenib: 7 patients as a result of disease progression, 2 patients as a result of nondermatologic toxicity, and 1 patient as a result of dermatologic toxicity.
  • CONCLUSION: These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK.
  • [MeSH-major] Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Drug Eruptions / etiology. Keratosis, Actinic / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. Skin Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Genitourin Cancer. 2009 Jan;7(1):9-10 [19213661.001]
  • (PMID = 19213663.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS773866; NLM/ PMC4825856
  •  go-up   go-down


60. El-Zawahry MB, Abdel El-Hameed El-Cheweikh HM, Abd-El-Rahman Ramadan S, Ahmed Bassiouny D, Mohamed Fawzy M: Ultrasound biomicroscopy in the diagnosis of skin diseases. Eur J Dermatol; 2007 Nov-Dec;17(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound biomicroscopy in the diagnosis of skin diseases.
  • We aimed to evaluate the accuracy of ultrasound biomicroscopy (UBM) in the diagnosis of eight skin disorders namely, morphea, keloid, lichen planus, chronic eczema, psoriasis, port wine stain, seborrheic keratosis, and photo-aged skin, through correlation of its findings with clinical and pathological assessment.
  • In morphea, the dermal echogenicity was increased and the thickness of morphea plaques correlated significantly with disease severity.
  • Seborrheic keratosis appeared as a sound shadow.
  • We conclude that UBM is a non-invasive diagnostic tool in dermatology which can be used to give valuable information about disease progress and the effectiveness of therapy.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951126.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


61. Albares Tendero MP, Belinchón Romero I, Ramos Rincón JM, Sánchez Payá J, Costa AL, Pérez Crespo M, Silvestre Salvador JF: Dermatoses in Latin American immigrants seen in a tertiary hospital. Eur J Dermatol; 2009 Mar-Apr;19(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparative study of dermatoses adjusted for age and sex, found a greater frequency of eczema, alopecia, melasma, herpes simplex, pilar keratosis, xerosis, and scabies (p < 0.01) in the Latin American population.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106052.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Ruiz-Rodríguez R, López L, Candelas D, Pedraz J: Photorejuvenation using topical 5-methyl aminolevulinate and red light. J Drugs Dermatol; 2008 Jul;7(7):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A randomized, prospective, split-face comparison study of 10 white, adult patients with moderate photodamage, Fitzpatrick skin types 2 or 3, and no occurrence of actinic keratosis was performed.
  • CONCLUSION: Methyl aminolevulinic-photodynamic therapy with red light can improve fine lines, tactile roughness and skin tightness in patients with moderate photoaging and no occurrence of actinic keratosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664154.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


63. de Berker D, McGregor JM, Hughes BR, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee: Guidelines for the management of actinic keratoses. Br J Dermatol; 2007 Feb;156(2):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of actinic keratoses.
  • Following this meeting one of the authors (J.M.M.) was invited to draw up guidelines for the management of actinic keratoses by the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee.
  • Relevant evidence was sought using the search terms 'solar keratosis' and 'actinic keratosis' in Medline from 1966 onwards.
  • [MeSH-major] Keratosis / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Dermatol. 2008 Apr;158(4):873
  • (PMID = 17223860.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  •  go-up   go-down


64. Wollina U, Nelskamp C, Scheibe A, Fassler D, Schmidt WD: Fluorescence--remission sensoring of skin tumours: preliminary results. Skin Res Technol; 2007 Nov;13(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using this technology, we performed a pilot study in 19 patients with 30 NMSC-suspicious lesions including: actinic keratosis (n=10), basal cell carcinoma (BCC; n=16) and squamous cell carcinoma (SCC; n=4 with two in situ carcinomas).
  • The fluorescence differences at 430 nm allow a differentiation between actinic keratoses and BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis / pathology. Skin Neoplasms / pathology. Spectroscopy, Near-Infrared / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Dermatology / instrumentation. Dermatology / methods. Dermoscopy. Diagnosis, Differential. Female. Fluorescence. Humans. Male. Pilot Projects. Reproducibility of Results. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908200.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


65. Silva RS, Fonseca JC, Obadia D: Case for diagnosis. Erythromelanosis follicularis faciei et colli. An Bras Dermatol; 2010 Nov-Dec;85(6):923-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case for diagnosis. Erythromelanosis follicularis faciei et colli.
  • Erythromelanosis follicularis faciei et colli is a rare disease of unknown etiology characterized by symmetric erythematous brownish hyperpigmentation on the frontal, malar and temporal areas associated with involvement of the pilary follicle.
  • It is common to present pilar keratosis on the shoulders and neck.
  • [MeSH-major] Darier Disease / pathology. Facial Dermatoses / pathology. Hyperpigmentation / pathology. Melanosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308325.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


66. Fai D, Arpaia N, Romano I, Vestita M, Cassano N, Vena GA: Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients. G Ital Dermatol Venereol; 2009 Jun;144(3):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
  • AIM: Topical photodynamic therapy (PDT) with methyl-aminolevulinate (MAL) is widely used for the management of actinic keratoses (AK) and non-melanoma skin cancers (NMSCs).
  • METHODS: The medical records selected concerned all patients who completed the MAL-PDT regimen (one single session for AK and two sessions one week apart for NMSCs) and who underwent post-treatment assessments over a follow-up period of at least 12 months.
  • RESULTS: Present case series included a total of 462 patients: 210 patients with AK, 228 subjects with 348 basal cell carcinomas (BCCs), 213 of nodular type (nBCC) and 135 of superficial type (sBCC), 17 patients with Bowen's disease and seven with squamous cell carcinoma.
  • On the whole, following a single session, complete clearance of AK was achieved in 79% of patients at three months and in 68.1% at 12 months.
  • Our results, even if obtained in very few cases, indicate that Bowen's disease is very responsive to MAL-PDT, unlike microinvasive or invasive SCC.
  • CONCLUSIONS: Our experience confirms that MAL-PDT is a valid approach to patients with AK, BCC and Bowen's disease, with an acceptable tolerability profile and a very low risk of complications.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Drug Evaluation. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / drug therapy. Pain / etiology. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528909.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


67. Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, Zangen DH, Raas-Rothschild A, Ben-Neriah Z, Shweiki S, Elpeleg O, Zlotogorski A: The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol; 2008 Jul;59(1):79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of cutaneous hyperpigmented, hypertrichotic, and indurated patches associated with hearing loss, short stature, cardiac anomalies, hepatosplenomegaly, scrotal masses, and hypogonadism has not, to our knowledge, been previously recognized as a disease entity.
  • Cutaneous histopathologic examination showed hyperpigmentation of the basal layer with seborrheic-keratosis-like acanthosis, histiocytic infiltration, and a perivascular mononuclear infiltrate with plasma cells and mast cells throughout the dermis and subcutaneous fat.
  • CONCLUSIONS: We suggest that our patients represent a novel multisystemic autosomal recessive inherited disorder.
  • [MeSH-major] Hearing Loss, Sensorineural / diagnosis. Hyperpigmentation / diagnosis. Hypertrichosis / diagnosis. Skin Diseases, Genetic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biopsy. Consanguinity. Female. Fibrosis. Genital Diseases, Male / diagnosis. Heart Defects, Congenital / diagnosis. Hepatomegaly / diagnosis. Humans. Lymph Nodes / pathology. Male. Phenotype. Skin / pathology. Splenomegaly / diagnosis. Syndrome

  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2009 Oct;61(4):725-7 [19664849.001]
  • [CommentIn] J Am Acad Dermatol. 2009 Aug;61(2):365 [19615552.001]
  • (PMID = 18410979.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Legoupil D, Lemasson G, Davaine AC, Misery L: [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases]. Ann Dermatol Venereol; 2007 Jan;134(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases].
  • Clinically, it is associated with rosaceiform dermatosis of the face that begins in childhood, and profuse keratotic lesions resembling seborrheic keratoses, seen predominantly on the trunk, the tops of the limbs and the scalp.
  • We report two cases of Bowen's disease and cutaneous epidermoid carcinoma in Haber's syndrome patients.
  • Histological examination of a biopsy sample confirmed the clinical diagnosis of Bowen's disease.
  • We propose the hypothesis of transformation of the keratoses seen in seborrheic keratosis.
  • The use of imiquimod to treat lesions in patients with Bowen's disease resulted in complete cure.
  • [MeSH-major] Bowen's Disease / complications. Carcinoma, Squamous Cell / complications. Keratosis / complications. Neoplasms, Multiple Primary / complications. Rosacea / complications. Skin Neoplasms / complications


69. Ashton KJ, Carless MA, Griffiths LR: Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer; 2005 Jul;43(3):239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose in this review is to discuss the cytogenetic findings on a number of nonmelanoma skin cancers, including squamous- and basal cell carcinomas, keratoacanthoma, squamous cell carcinoma in situ (Bowen's disease), and solar keratosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15834942.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


70. Mauerer A, Betz RC, Pasternack SM, Landthaler M, Hafner C: Generalized solar lentigines in a patient with a history of radon exposure. Dermatology; 2010;221(3):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized solar lentigines in a patient with a history of radon exposure.
  • The histopathology of the lesions was compatible with a diagnosis of solar lentigines (SLs) or flat seborrhoeic keratosis.
  • Genetic analysis identified a p.S249C FGFR3 hotspot mutation in 1 lesion, supporting the diagnosis of SLs.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Radon.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664185.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; Q74S4N8N1G / Radon
  •  go-up   go-down


71. Hoshina D, Akiyama M, Hata H, Aoyagi S, Sato-Matsumura KC, Shimizu H: Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis. Clin Exp Dermatol; 2007 Jan;32(1):54-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis.
  • An association between seborrhoeic keratosis (SK) and malignant tumours is considered to be rare.
  • We observed a case of eccrine porocarcinoma and Bowen's disease (BD) occurring synchronously, forming one lesion in a SK on the abdomen.
  • It is controversial whether malignant neoplasms arising in SK occur only by chance or if pre-existing SK plays a role in pathogenesis.
  • This case suggests an implication of pre-existing SK in the subsequent development of both BD and eccrine porocarcinoma.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma / pathology. Eccrine Glands. Keratosis, Seborrheic / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2008 May;33(3):350-1 [18261140.001]
  • (PMID = 17004985.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Kim JH, Bae HW, Lee KK, Kim TI, Kim EK: Seborrheic keratosis of the conjunctiva: a case report. Korean J Ophthalmol; 2009 Dec;23(4):306-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosis of the conjunctiva: a case report.
  • Seborrheic keratosis is a benign epithelial neoplasia that occurs mainly in the skin of the eyelids and face.
  • We describe a case of seborrheic keratosis of the conjunctiva confirmed by histopathology.
  • Clinically, a diagnosis of conjunctival papilloma was made, and a mass excision was performed.
  • With the above findings, a diagnosis of conjunctival seborrheic keratosis was established.
  • The occurrence of seborrheic keratosis on the conjunctiva is rare.
  • In this case, seborrheic keratosis was confirmed by pathologic report despite its similar appearance with papilloma.
  • Seborrheic keratosis should be considered in the differential diagnosis of conjunctival lesions.
  • [MeSH-major] Conjunctival Diseases / diagnosis. Keratosis, Seborrheic / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Microscopy, Acoustic. Ophthalmologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Ophthalmol. 2004 Jun;52(2):154-5 [15283223.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Arch Dermatol Res. 1995;287(6):612-5 [7487151.001]
  • [Cites] Arch Soc Esp Oftalmol. 2006 Apr;81(4):217-9 [16688646.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Ophthalmology. 1999 Aug;106(8):1516-20 [10442897.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):278-82 [8806962.001]
  • (PMID = 20046694.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789958
  • [Keywords] NOTNLM ; Conjunctival mass / Papilloma / Seborrheic keratosis
  •  go-up   go-down


73. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM: PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol; 2009 Feb;50(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
  • The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis.
  • This randomized, double-blind, vehicle-controlled, phase IIa study investigated the safety (and secondarily the efficacy) of two applications of ingenol mebutate gel in 58 patients with biopsy-confirmed actinic keratosis.
  • Ingenol mebutate gel is being developed as a short-course topical therapy for actinic keratosis and non-melanoma skin cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Diterpenes / therapeutic use. Esters / therapeutic use. Keratosis, Actinic / drug therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178487.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / Antineoplastic Agents, Phytogenic; 0 / Diterpenes; 0 / Esters; 0 / Gels
  •  go-up   go-down


74. Kothiwale SV, Mathur S: Partial expression of Papillon-Lefèvre Syndrome. Indian J Dent Res; 2008 Jul-Sep;19(3):264-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is characterized by palmar plantar keratosis and severe early-onset periodontitis affecting both deciduous and permanent dentition.
  • The patient exhibited palmar plantar keratosis and an isolated, moderately deep periodontal pocket in the third quadrant.
  • [MeSH-major] Papillon-Lefevre Disease / diagnosis

  • Genetic Alliance. consumer health - Papillon Lefevre syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797107.001).
  • [ISSN] 0970-9290
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


75. Minagawa A, Koga H: Dermoscopy of pigmented poromas. Dermatology; 2010 Aug;221(1):78-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Pigmented poromas mimic a number of skin tumors, including pigmented basal cell carcinomas, seborrheic keratosis and malignant melanoma, because they present various clinical, dermoscopic and histopathological features.
  • [MeSH-major] Dermoscopy. Pigmentation Disorders / diagnosis. Poroma / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratosis, Seborrheic / diagnosis. Male. Melanoma / diagnosis. Middle Aged. Retrospective Studies. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516657.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


76. Terada T: Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis. Int J Clin Oncol; 2010 Dec;15(6):608-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis.
  • A clinical diagnosis of basal cell carcinoma was made, and an excision with wide margins was performed.
  • The periphery of the tumor showed typical features of pigmented reticulated seborrheic keratosis.
  • This case suggests that pigmented Bowen disease can arise in pigmented reticulated seborrheic keratosis.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Basal Cell / complications. Keratosis, Seborrheic / complications. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dermatol Surg Oncol. 1988 Jul;14(7):765-9 [3292613.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] J Cutan Pathol. 1989 Dec;16(6):348-52 [2533222.001]
  • [Cites] Mt Sinai J Med. 1974 Nov-Dec;41(6):792-801 [4279330.001]
  • [Cites] J Cutan Pathol. 1978 Dec;5(6):361-7 [154527.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):440-4 [2145328.001]
  • [Cites] Br J Dermatol. 1991 Mar;124(3):287-90 [1826848.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):106-8 [16637805.001]
  • [Cites] Plast Reconstr Surg. 1998 Aug;102(2):453-5; discussion 456-8 [9703085.001]
  • (PMID = 20425131.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, Phase IV ALA-PDT Actinic Keratosis Study Group: Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol; 2006 Dec;155(6):1262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.
  • BACKGROUND: Actinic keratoses (AKs) are the most common epithelial precancerous lesions, especially among individuals with light complexions.
  • (ii) to characterize the histopathology of treated AK lesions that do not completely respond to ALA-PDT or recur in long-term follow up;.
  • (iii) to characterize the histopathology of untreated clinically diagnosed AK lesions in the study population at baseline; and (iv) to evaluate ALA-PDT in darker skin types than previously studied.
  • METHODS: Patients enrolled in this study had six to 12 discrete AK lesions, either on the face or the scalp.
  • Individual AK lesions designated for treatment were graded as either grade 1 (lesions slightly palpable and more easily felt than seen) or grade 2 (moderately thick AKs, easily seen and felt).
  • The target AK lesions in the per-protocol population clearing completely in the first and second months following a single ALA-PDT treatment (baseline) were 76% and 72%, respectively.
  • With respect to the lesions biopsied, 91% (127/139) were diagnosed histopathologically as AK, with the balance of lesions being SCC (nine of 139: 7%), basal cell carcinoma (one of 139: 0.7%) and other non-AK diagnoses (two of 139: 1%).
  • The clinical diagnosis of AK by investigators appeared to be accurate, with 91% (200/220) of the untreated clinically diagnosed AK lesions being histopathologically confirmed to be AK (AK, 142/220: 65%; advanced AK, 29/220: 13%; macular AK, 29/220: 13%).
  • The demographics of this study population are typical of a patient population with AK.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Facial Dermatoses / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Scalp Dermatoses / drug therapy


78. Burnett TJ, English JC 3rd, Ferris LK: Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol; 2010 Aug;9(8):1022-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
  • Food and Drug Administration (FDA) to treat actinic keratoses, non-facial superficial basal cell carcinomas and genital warts.
  • The authors report the case of a 56-year-old female who developed subacute cutaneous lupus erythematosus (SCLE), as well as severe autoimmune retinitis following a vigorous response to imiquimod 5% cream that was prescribed to treat actinic keratoses.
  • [MeSH-minor] Administration, Cutaneous. Autoimmune Diseases / chemically induced. Female. Humans. Keratosis, Actinic / drug therapy. Middle Aged. Retinitis / chemically induced. Retinitis / immunology. Severity of Illness Index

  • Genetic Alliance. consumer health - Cutaneous Lupus Erythematosus.
  • Genetic Alliance. consumer health - Lupus.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684157.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


79. Peris K, Micantonio T, Piccolo D, Fargnoli MC: Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges; 2007 Nov;5(11):970-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic features of actinic keratosis.
  • Actinic keratosis (AK) is a keratinocytic neoplasm that typically develops on sun-damaged skin of elderly individuals.
  • Only a few reports so far have described the dermoscopic diagnostic features of AK, mainly focusing on facial non-pigmented AKs.
  • A typical feature of facial non-pigmented AK is a composite pattern named "strawberry pattern", characterized by a background erythema/red pseudonetwork consisting of unfocused, large vessels located between the hair follicles, associated with prominent follicular openings surrounded by a white halo.
  • Dermoscopic characteristics of pigmented AK on the face include multiple slate-gray to dark-brown dots and globules around the follicular ostia, annular-granular pattern and brown to gray pseudonetwork.
  • Recognizing specific dermoscopic features of AK can be useful in guiding the clinician in the differential diagnosis of AK with melanocytic skin lesions such as LM and non-melanocytic lesions.
  • Histopathologic examination should be performed whenever clinical and/or dermoscopic differential diagnosis is inconclusive.
  • [MeSH-major] Dermoscopy / methods. Keratosis / pathology. Photosensitivity Disorders / pathology. Skin / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908179.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


80. Ko CJ, Iftner T, Barr RJ, Binder SW: Changes of epidermodysplasia verruciformis in benign skin lesions: the EV acanthoma. J Cutan Pathol; 2007 Jan;34(1):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These skin lesions included an intradermal nevus, a pigmented seborrheic keratosis, an isolated papule on the forearm, a perianal lesion, and an acantholytic acanthoma.
  • EV changes and EV-HPV can be found incidentally on biopsy in the absence of clinical EV; when such changes are the major histopathological finding in an isolated skin lesion, the lesion should be termed an EV acanthoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Keratosis, Seborrheic / pathology. Keratosis, Seborrheic / virology. Male. Middle Aged. Nevus / pathology. Nevus / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification


81. Zhang Y, Brodell RT, Mostow EN, Vinyard CJ, Marie H: In vivo skin elastography with high-definition optical videos. Skin Res Technol; 2009 Aug;15(3):271-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Continuous measurements of biomechanical properties of skin provide potentially valuable information to dermatologists for both clinical diagnosis and quantitative assessment of therapy.
  • In the three cases presented in this article (hypertrophic lichen planus, seborrheic keratosis and psoriasis vulgaris), abnormal tissues associated with the skin diseases were successfully identified in the elastograms.
  • CONCLUSIONS: Optical elastography is a promising imaging modality that is capable of capturing disease-induced property changes.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624423.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


82. Yao D, Alexander CL, Quinn JA, Chan WC, Wu H, Greenhalgh DA: Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci; 2008 May 15;121(Pt 10):1758-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RU486-treated HK1.Fos/Delta5Pten flx mice exhibited hyperplasia, hyperkeratosis and tumours that progressed to highly differentiated keratoacanthomas, rather than to carcinomas, owing to re-expression of high p53 and p21 WAF levels.
  • Despite elevated MAP kinase activity, cyclin D1 and cyclin E2 overexpression, and increased AKT activity that produced areas of highly proliferative papillomatous keratinocytes, increasing levels of GSK3beta inactivation induced a novel p53/p21 WAF expression profile, which subsequently halted proliferation and accelerated differentiation to give the hallmark keratosis of keratoacanthomas.
  • [MeSH-minor] Animals. Cyclin D. Cyclins / metabolism. Disease Progression. Mice. Mifepristone / pharmacology. Oncogene Protein v-akt / metabolism. Repressor Proteins / metabolism. Skin Neoplasms / metabolism


83. Korting HC, Schäfer-Korting M: Carriers in the topical treatment of skin disease. Handb Exp Pharmacol; 2010;(197):435-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carriers in the topical treatment of skin disease.
  • Starting with the liposomes, various types of nanosized and microsized drug carriers have been developed to increase the notoriously low penetration of active agents into the skin, which limits not only the topical therapy of skin disease but also transdermal therapy.
  • Today, liposome- and microsponge-based preparations are approved for dermatomycosis, acne and actinic keratosis.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20217539.001).
  • [ISSN] 0171-2004
  • [Journal-full-title] Handbook of experimental pharmacology
  • [ISO-abbreviation] Handb Exp Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Drug Carriers
  • [Number-of-references] 135
  •  go-up   go-down


84. Green AC, McBride P: Squamous cell carcinoma of the skin (non-metastatic). BMJ Clin Evid; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Does the use of sunscreen help prevent cutaneous squamous cell carcinoma and solar keratosis?

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4):300-5 [12879331.001]
  • [Cites] Surg Gynecol Obstet. 1966 Feb;122(2):245-8 [5901291.001]
  • [Cites] Arch Surg. 1974 Jan;108(1):50-1 [4808574.001]
  • [Cites] Cancer. 1989 May 1;63(9):1863-71 [2702595.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):383-6 [1951174.001]
  • [Cites] J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):467-84 [1564155.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):574-7 [1463102.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):512-8 [8504041.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):589-96 [7478649.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):89-93 [10758309.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1061-9 [11240248.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Plast Reconstr Surg. 2003 Jul;112(1):57-63 [12832877.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):628-34 [9610717.001]
  • [Cites] J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):960-6 [9632005.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1304-9 [10433619.001]
  • [Cites] Head Neck. 1999 Sep;21(6):526-30 [10449668.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Med J Aust. 2006 Jan 2;184(1):6-10 [16398622.001]
  • [Cites] Prev Med. 2006 Mar;42(3):171-6 [16325898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1301-7 [17535230.001]
  • [Cites] Int Arch Occup Environ Health. 2009 Feb;82(3):357-63 [18649084.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):457-61 [18218349.001]
  • (PMID = 21733203.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Other-IDs] NLM/ PMC2907617
  •  go-up   go-down


85. Kacerovská D, Pizinger K, Majer F, Smíd F: Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study. Photochem Photobiol; 2008 May-Jun;84(3):779-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ).
  • The study was carried out on 34 patients--eight with actinic keratoses (AKs), 21 with BCC and five with Bowen's disease.
  • The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen's disease.
  • A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen's disease.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Hypericum. Perylene / analogs & derivatives. Photochemotherapy / methods. Plant Preparations / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratosis / drug therapy. Male. Middle Aged. Molecular Structure. Phytotherapy. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179625.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Preparations; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


86. Ritter CG, Kuhl IC, Lenhardt C, Weissbluth ML, Bakos RM: Photodynamic therapy with delta-aminolevulinic acid and light-emitting diodes in actinic keratosis. An Bras Dermatol; 2010 Sep-Oct;85(5):639-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with delta-aminolevulinic acid and light-emitting diodes in actinic keratosis.
  • New light sources are being evaluated for use in the treatment of actinic keratoses.
  • OBJECTIVES: To evaluate the efficacy of photodynamic therapy with delta-aminolevulinic acid using a light emitting diode device as a light source in the treatment of actinic keratoses of the face and upper limbs.
  • METHODS: Eighteen patients with actinic keratoses of the face or upper limbs received an application of a 20% delta-aminolevulinic acid cream and were submitted to diode light irradiation at a wavelength of 630 nm.
  • RESULTS: A total of 328 actinic keratoses were treated, obtaining complete cure in 210 (64.0%) after 24 weeks.
  • CONCLUSION: Photodynamic therapy with a diode light emitting source proved effective and well-tolerated for the treatment of actinic keratoses, with results similar to those reported in the literature with other light sources.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152788.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


87. Augustine M, Jayaseelan E: Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris. Indian J Dermatol Venereol Leprol; 2008 Jan-Feb;74(1):47-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris.
  • The possibility of this condition being genetically related to keratosis pilaris as well as being a variant of keratosis rubra pilaris is also discussed.
  • [MeSH-major] Darier Disease / pathology. Erythema / pathology. Facial Dermatoses / pathology. Hyperpigmentation / pathology. Melanosis / pathology

  • Genetic Alliance. consumer health - Darier Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187825.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


88. Berlin JM: Current and emerging treatment strategies for the treatment of actinic keratosis. Clin Cosmet Investig Dermatol; 2010;3:119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and emerging treatment strategies for the treatment of actinic keratosis.
  • Actinic keratoses are encountered by physicians worldwide on a daily basis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):1050-3 [11359396.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2833-9 [15087400.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Int J Dermatol. 2007 Jan;46(1):12-8 [17214714.001]
  • [Cites] J Transl Med. 2007;5:7 [17257431.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2523-30 [19382202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] J Am Acad Dermatol. 2009 Jun;60(6):934-43 [19467365.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):43-7 [9922011.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):94-100 [11841372.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):22-9 [12353677.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7515-9 [14612553.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:9-14 [14616338.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):467-73 [15837864.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):808-10 [16181465.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Cutis. 2007 Apr;79(4 Suppl):18-28 [17508492.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):665-7 [1791225.001]
  • [Cites] Cutis. 2008 Jun;81(6):509-16 [18666394.001]
  • [Cites] J Am Acad Dermatol. 2010 Apr;62(4):573-81 [20133012.001]
  • [Cites] J Am Acad Dermatol. 2010 Apr;62(4):582-90 [20133013.001]
  • [Cites] Med J Aust. 1990 Jan 15;152(2):62-6 [2296232.001]
  • [Cites] Arch Dermatol. 1970 Feb;101(2):132-9 [5413250.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Am Acad Dermatol. 1995 Jan;32(1):95-8 [7529779.001]
  • [Cites] Dermatol Surg. 1995 Feb;21(2):184 [7894943.001]
  • [Cites] Dermatol Surg. 1997 Mar;23(3):191-6 [9145962.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):885-9 [9357496.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1239-42 [9382562.001]
  • [Cites] J Am Acad Dermatol. 1998 Jan;38(1):77-80 [9448209.001]
  • [Cites] Br J Dermatol. 1962 Jun;74:229-36 [13891467.001]
  • (PMID = 21437066.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3047952
  • [Keywords] NOTNLM ; 5-fluorouracil / actinic keratoses / squamous cell carcinoma
  •  go-up   go-down


89. Rallan D, Bush NL, Bamber JC, Harland CC: Quantitative discrimination of pigmented lesions using three-dimensional high-resolution ultrasound reflex transmission imaging. J Invest Dermatol; 2007 Jan;127(1):189-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those subsequently classified as malignant melanoma (MM), seborrheic keratosis (SK), and benign nevi by a consultant dermatologist (n=87) were imaged by high-resolution ultrasound-reflex transmission imaging.
  • Using surrounding normal skin as a control, numerical sonographic parameters were derived for each lesion giving a relative measure of surface sound reflectance, intra-lesional sound reflection, total sound attenuation, and the relative uniformity of each parameter across the tumor.
  • [MeSH-major] Imaging, Three-Dimensional. Keratosis, Seborrheic / ultrasonography. Melanoma / ultrasonography. Nevus / ultrasonography. Skin Neoplasms / ultrasonography


90. Tomková H, Vaňková L, Pock L, Šternberský J: Segmental Darier's disease postpartum and following tubal ligation. Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec;19(4):31-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental Darier's disease postpartum and following tubal ligation.
  • Segmental Darier's disease is a rare clinical variant of autosomal dominant Darier's disease (keratosis follicularis) exhibiting eruptions in a unilateral arrangement following the lines of Blaschko.
  • It occurs in approximately 10% of patients with Darier's disease.
  • We report two cases of type 1 segmental Darier's disease that appeared a few months after childbirth; in one case, recurrence of the disease occurred after tubal ligation.
  • [MeSH-major] Darier Disease / pathology. Puerperal Disorders / pathology. Sterilization, Tubal / adverse effects

  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • MedlinePlus Health Information. consumer health - Tubal Ligation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21390479.001).
  • [ISSN] 1581-2979
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


91. Greer RO Jr, Meyers A, Said SM, Shroyer KR: Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker? Int J Oral Maxillofac Surg; 2008 Sep;37(9):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study correlates the expression of p16(INK4a) and p53 with the detection of high risk human papillomavirus (HPV) in three clinical grades of smokeless tobacco keratosis (STK) as compared with patients without a history of smokeless tobacco use.
  • At least focal p16(INK4a) expression was detected in Grade I, II and III STK, SCC and control samples of alveolar ridge keratoses (ARK).
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. DNA, Viral / isolation & purification. Humans. Immunohistochemistry. Keratosis / metabolism. Papillomaviridae / genetics. Papillomavirus Infections / diagnosis. Severity of Illness Index. Tobacco, Smokeless / adverse effects. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18606525.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


92. Seckin D, Cerman AA, Yildiz A, Ergun T: Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report. J Drugs Dermatol; 2009 May;8(5):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report.
  • OBJECTIVE: To determine whether actinic keratoses may benefit from the antiproliferative and prodifferentiative effects of topical vitamin D.
  • The total number of actinic keratoses (AKs), diameters and total scores of the target lesions were determined at each visit.
  • CONCLUSION: Topical calcipotriol may show promise in the treatment of actinic keratoses.
  • [MeSH-major] Calcitriol / analogs & derivatives. Dermatologic Agents / administration & dosage. Dermatologic Agents / therapeutic use. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537367.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 143NQ3779B / calcipotriene; FXC9231JVH / Calcitriol
  •  go-up   go-down


93. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol; 2007 Dec;157 Suppl 2:34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
  • BACKGROUND: Actinic keratoses (AK) frequently occur on sun-exposed skin and are considered as in situ squamous cell carcinoma.
  • OBJECTIVE: This study compared the initial and 12-month clinical clearance, histological clearance, and cosmetic outcomes of topically applied 5% imiquimod (IMIQ) cream, 5% 5-fluorouracil (5-FU) ointment and cryosurgery for the treatment of AK.
  • CONCLUSION: Imiquimod treatment of AK resulted in superior sustained clearance and cosmetic outcomes compared with cryosurgery and 5-FU.
  • It should be considered as a first line therapy for sustained treatment of AK.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cryosurgery. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067630.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Nindl I, Köhler A, Gottschling M, Forschner T, Lehmann M, Meijer CJ, Snijders PJ, Stockfleth E: Extension of the typing in a general-primer-PCR reverse-line-blotting system to detect all 25 cutaneous beta human papillomaviruses. J Virol Methods; 2007 Dec;146(1-2):1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • beta-Papillomaviruses (PV) seem to be involved in the pathogenesis of cutaneous squamous cell carcinoma and its early stage actinic keratosis.
  • In this study, typing was extended of a previously described consensus primer-mediated beta- and gamma-cutaneous HPV PCR method followed by reverse-line-blotting (BGC-PCR/RLB) to detect all 25 known beta-PV and to examine their prevalence in actinic keratosis.
  • Subsequently, tumor and normal skin tissues were collected from 75 patients with actinic keratosis, allowing typing for a total of 25 beta- and 5 gamma-types.
  • HPV DNA was detected in 45% of actinic keratosis and in 33% of normal skin by BGC-PCR, and at least one of the six added beta-types was present in 19% of actinic keratoses and in 13% of normal skin.
  • [MeSH-major] Betapapillomavirus / isolation & purification. Blotting, Southern / methods. DNA Probes, HPV. Keratosis / virology. Papillomavirus Infections / virology. Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604130.001).
  • [ISSN] 0166-0934
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


95. Ko CJ, Barr RJ, Subtil A, McNiff JM: Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis. J Cutan Pathol; 2008 Mar;35(3):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acantholytic dyskeratotic acanthoma: a variant of a benign keratosis.
  • Lesions were most often found on the trunk as a solitary papule, for which the clinical diagnosis was often basal cell carcinoma.
  • Confluent acantholysis and dyskeratosis is a histologic pattern that may present as a solitary keratosis.
  • [MeSH-major] Acantholysis / pathology. Acanthoma / pathology. Keratosis / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251744.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


96. de Giorgi V, Massi D, Sestini S, Alfaioli B, Carelli G, Carli P: Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report. Br J Dermatol; 2005 Apr;152(4):787-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report.
  • Histologically, the lesion was a melanocytic compound naevus and a BCC with a seborrhoeic keratosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Dermoscopy / methods. Diagnosis, Differential. Female. Hip. Humans. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840116.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Alexiades-Armenakas M: Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers. Dermatol Clin; 2007 Jan;25(1):25-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers.
  • In particular, LP PDL PDT has been shown to be safe and effective in the treatment of actinic keratoses, actinic cheilitis, photodamage, and acne vulgaris with minimal discomfort, rapid treatment and recovery, and excellent posttreatment cosmesis.
  • [MeSH-major] Acne Vulgaris / drug therapy. Aminolevulinic Acid / therapeutic use. Cheilitis / drug therapy. Keratosis / drug therapy. Low-Level Light Therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Ultraviolet Rays / adverse effects

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • MedlinePlus Health Information. consumer health - Acne.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126739.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 72
  •  go-up   go-down


98. Merk HF: Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol; 2007 Jan;46(1):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical diclofenac in the treatment of actinic keratoses.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / therapeutic use. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. Precancerous Conditions / drug therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214714.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  • [Number-of-references] 40
  •  go-up   go-down


99. Chen GJ, Feldman SR, Williford PM, Hester EJ, Kiang SH, Gill I, Fleischer AB Jr: Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg; 2005 Jan;31(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer.
  • BACKGROUND: Development of actinic keratoses (AK) involves some of the same processes as nonmelanoma skin cancer and may serve as a marker for overall increased risk of skin cancer.
  • OBJECTIVE: The objective of this study was to examine the risk of developing skin cancer in an elderly population with and without AK.
  • RESULTS: Multivariate analysis showed that the risk (odds ratio [OR]) of developing nonmelanoma or melanoma was increased more than sixfold (p < or = .0001) in patients with AK.
  • CONCLUSION: Using data from a nationally representive sample of the Medicare population, this study demonstrates that elders with AK are a population at high risk of developing cutaneous cancer.
  • [MeSH-major] Keratosis / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720095.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / T32 AR07411
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


100. Christensen E, Bofin A, Gudmundsdóttir I, Skogvoll E: Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear. Cytopathology; 2008 Oct;19(5):316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of basal cell carcinoma and actinic keratosis, using Papanicolaou and May-Grünwald-Giemsa stained cutaneous tissue smear.
  • The aim of this study was to compare and evaluate the diagnostic performance of scrape cytology using two different cytological staining techniques, and to evaluate additional touch imprint cytology, with that of histopathology of basal cell carcinoma (BCC) and actinic keratosis (AK).
  • METHODS: We investigated 50 BCC and 28 AK histologically verified lesions, from 41 and 25 patients, respectively.
  • RESULTS: Scrape cytodiagnosis agreed with histopathology in 48 (Pap) and 47 (MGG) of the 50 BCC cases, and in 26 of 28 (Pap) and 21 of 26 (MGG) AK cases, yielding sensitivities of 96%, 94%, 93% and 81%, respectively.
  • No significant difference in sensitivity between the two staining methods was found but a trend towards higher Pap sensitivity for AK was noted (P = 0.10).
  • Touch imprint cytology confirmed histopathology in 38 of the 77 cases of BCC and AK.
  • CONCLUSION: Cytological diagnosis with either Pap or MGG stain for BCC and AK is reliable, and differentiates well between BCC and AK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Coloring Agents. Cytodiagnosis / methods. Eosine Yellowish-(YS) / metabolism. Keratosis / diagnosis. Methylene Blue / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cytopathology. 2008 Oct;19(5):333-4; author reply 334 [18513288.001]
  • (PMID = 17916094.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down






Advertisement